← Back to Screener
IDEAYA Biosciences, Inc. Common Stock (IDYA)
Price$33.60
Favorite Metrics
Price vs S&P 500 (26W)18.62%
Price vs S&P 500 (4W)-1.94%
Market Capitalization$2.95B
All Metrics
Book Value / Share (Quarterly)$11.65
P/TBV (Annual)5.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)62.54%
Cash Flow / Share (Quarterly)$-0.84
Price vs S&P 500 (YTD)-6.74%
Net Profit Margin (TTM)16.45%
EPS (TTM)$-1.30
10-Day Avg Trading Volume2.57M
EPS Excl Extra (TTM)$-1.30
Revenue Growth (5Y)62.10%
EPS (Annual)$-1.28
ROI (Annual)-11.11%
Net Profit Margin (5Y Avg)-949.88%
Cash / Share (Quarterly)$7.28
Revenue Growth QoQ (YoY)55.37%
ROA (Last FY)-10.25%
Revenue Growth TTM (YoY)3024.43%
EBITD / Share (TTM)$-1.63
ROE (5Y Avg)-17.70%
Operating Margin (TTM)6.35%
Cash Flow / Share (Annual)$-0.84
P/B Ratio2.88x
P/B Ratio (Quarterly)2.96x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)12.97x
ROA (TTM)-10.21%
EPS Incl Extra (Annual)$-1.28
Current Ratio (Annual)11.34x
Quick Ratio (Quarterly)10.97x
3-Month Avg Trading Volume1.09M
52-Week Price Return96.72%
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$8.67
P/S Ratio (Annual)13.49x
Asset Turnover (Annual)0.20x
52-Week High$39.28
Operating Margin (5Y Avg)-1124.28%
EPS Excl Extra (Annual)$-1.28
CapEx CAGR (5Y)37.04%
Tangible BV CAGR (5Y)102.18%
26-Week Price Return25.51%
Quick Ratio (Annual)10.97x
13-Week Price Return-6.82%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.34x
Enterprise Value$2,837.726
Revenue / Share Growth (5Y)25.61%
Asset Turnover (TTM)0.19x
Book Value / Share Growth (5Y)11.63%
Revenue / Employee (Annual)$2
Pretax Margin (Annual)-51.99%
Cash / Share (Annual)$7.28
3-Month Return Std Dev46.98%
Net Income / Employee (TTM)$-1
ROE (Last FY)-11.11%
EPS Basic Excl Extra (Annual)$-1.28
Receivables Turnover (TTM)73.20x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.30
Receivables Turnover (Annual)73.20x
ROI (TTM)-11.05%
P/S Ratio (TTM)13.49x
Pretax Margin (5Y Avg)-949.88%
Revenue / Share (Annual)$2.47
Tangible BV / Share (Annual)$7.25
Price vs S&P 500 (52W)62.09%
Year-to-Date Return-2.81%
5-Day Price Return3.86%
EPS Normalized (Annual)$-1.28
ROA (5Y Avg)-16.05%
Net Profit Margin (Annual)-51.99%
Month-to-Date Return0.84%
Cash Flow / Share (TTM)$-1.89
EBITD / Share (Annual)$-1.77
Operating Margin (Annual)-72.84%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-17.70%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.30
P/TBV (Quarterly)4.01x
P/B Ratio (Annual)2.96x
Pretax Margin (TTM)16.45%
Book Value / Share (Annual)$11.65
Price vs S&P 500 (13W)-9.20%
Beta0.06x
P/FCF (Annual)53.68x
Revenue / Share (TTM)$2.47
ROE (TTM)-11.05%
52-Week Low$16.07
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.24
4.24
4.24
4.24
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IDYAIDEAYA Biosciences, Inc. Common Stock | 13.49x | 3024.43% | — | — | $33.60 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
IDEAYA Biosciences is an oncology-focused precision medicine company developing targeted cancer therapies selected using molecular diagnostics and biomarker validation. It combines small molecule drug discovery with translational research to identify patient populations most likely to benefit from its treatments. The company has six clinical-stage candidates and multiple earlier-stage preclinical programs in development.